Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute. Pazopanib (Votrient) and sunitinib (Sutent), both recently approved as first-line treatments for advanced renal cell cancer, had similar benefits in delaying progression of the disease, but the safety profile and many measures of quality of life favored pazopanib, suggesting a potential shift in standard of care in metastatic kidney cancer...
More...
More...